Crestor (Rosuvastatin) Pediatric Dosing for Children Under 12

Who Qualifies for Rosuvastatin Under Age 12

Only children with a confirmed diagnosis of familial hypercholesterolemia (FH) should receive rosuvastatin before age 12. The FDA label restricts pediatric use to two populations: children aged 8 and older with HeFH who have not reached LDL-C goals after an adequate trial of diet therapy, and children aged 7 and older with HoFH [1]. Pediatric statin prescriptions outside these indications remain off-label.

FH is the most common reason a child under 12 needs a statin. Heterozygous FH affects roughly 1 in 250 individuals, meaning many children carry it without a diagnosis [2]. The 2011 NHLBI Expert Panel on Cardiovascular Health and Risk Reduction in Children and Adolescents recommended universal lipid screening between ages 9 and 11, with selective screening as early as age 2 if family history warrants it [3]. That guideline states: "For children aged 10 years and older with an LDL-C persistently ≥190 mg/dL, or ≥160 mg/dL with a positive family history or additional risk factors, statin therapy should be considered after a 6-month dietary intervention." Children diagnosed with HoFH often present even earlier, with LDL-C values exceeding 400 mg/dL in untreated cases. These patients face accelerated atherosclerosis and may develop aortic valve disease before adolescence, making early pharmacologic intervention a clinical necessity rather than a preference [4].

A genetic diagnosis through cascade screening (testing relatives of a known FH proband) provides the strongest confirmation. Clinical criteria alone can suffice when LDL-C exceeds threshold values and a parent carries a confirmed diagnosis.

FDA-Approved Dosing by Age and FH Type

Dosing differs based on FH subtype and the child's age. The distinctions matter.

For heterozygous FH in children aged 8 to 9, the FDA-approved Crestor prescribing information specifies a starting dose of 5 mg orally once daily, with a maximum dose of 10 mg per day [1]. For HeFH in children aged 10 to 11, the starting dose remains 5 mg daily, but the maximum increases to 20 mg once daily. The lower ceiling for younger children reflects limited pharmacokinetic data in patients under 10 and a conservative approach to musculoskeletal safety during growth [1].

For homozygous FH in children aged 7 to 11, the recommended dose is 20 mg once daily [1]. This higher starting dose reflects the severity of HoFH, where LDL-C levels are dramatically elevated and partial responses to statins are expected because of reduced or absent LDL receptor function.

All doses are administered as a single daily oral tablet. Rosuvastatin can be taken with or without food. No liquid formulation is commercially available, though the tablets can be crushed and mixed with water for children who cannot swallow pills (stability data support immediate administration after crushing) [1].

Quick-reference dosing table:

| Indication | Age range | Starting dose | Maximum dose | |---|---|---|---| | HeFH | 8 to 9 years | 5 mg/day | 10 mg/day | | HeFH | 10 to 11 years | 5 mg/day | 20 mg/day | | HoFH | 7 to 11 years | 20 mg/day | 20 mg/day |

PLUTO Trial: The Primary Pediatric Evidence

The PLUTO trial (Pediatric Lipid-Reduction Using Rosuvastatin in a Randomized, Double-Blind, Placebo-Controlled Trial) is the registration study that supported FDA pediatric approval. Published by Avis et al. in Pediatrics (2010), it enrolled 176 children and adolescents aged 6 to 17 with HeFH across 22 centers worldwide [5].

Participants received rosuvastatin 5 mg, 10 mg, or 20 mg daily, or placebo, for 12 weeks. The primary endpoint was percent change in LDL-C from baseline. Results were decisive. Rosuvastatin 5 mg reduced LDL-C by 38.3%, the 10 mg dose reduced it by 44.6%, and the 20 mg dose produced a 49.7% reduction, all compared to a 0.7% increase with placebo (P<0.001 for all comparisons) [5].

Safety signals were mild. No child discontinued due to adverse events. Creatine kinase elevations occurred at rates comparable to placebo. The investigators reported no clinically meaningful effects on growth velocity, sexual maturation, or adrenal steroidogenesis over the 12-week treatment period [5]. A 40-week open-label extension confirmed sustained LDL-C lowering with no new safety signals, though the extension did not include children under age 8 [5].

One limitation deserves emphasis: the PLUTO trial included only 18 patients under age 10. The sub-10 cohort showed LDL-C reductions consistent with older children, but the small sample size means safety generalizations for this age group carry wider uncertainty.

How to Titrate and When to Adjust

Start low. Assess response at 4 weeks.

For an 8-year-old with HeFH starting at 5 mg daily, recheck a fasting lipid panel after 4 weeks of therapy. If LDL-C has not reached the treatment goal (typically a 50% reduction from baseline or an absolute LDL-C <130 mg/dL per the NHLBI pediatric guidelines), increase to 10 mg daily [3]. In children aged 8 to 9 to 10 mg is the ceiling. For children 10 and older, a second titration to 20 mg is permitted if 10 mg proves insufficient.

The National Lipid Association's 2015 pediatric FH recommendations reinforce this stepwise approach: "Titrate the statin dose to achieve at least a 50% reduction in LDL-C, using the lowest effective dose that reaches this target" [6]. Dose increases should occur no more frequently than every 4 weeks.

If a child on maximum-dose rosuvastatin (10 mg for ages 8 to 9, or 20 mg for ages 10+) still has an LDL-C above 130 mg/dL, options include adding ezetimibe (10 mg daily, FDA-approved as adjunct therapy in pediatric HeFH patients aged 10+) or referral to a pediatric lipid specialist for consideration of PCSK9 inhibitor therapy. Bile acid sequestrants (colesevelam) are another adjunct option approved for children 10 and older, though adherence is often poor due to taste and GI side effects.

Monitoring Requirements in Children Under 12

Pediatric statin monitoring extends beyond lipid panels. Growth surveillance is mandatory.

Before starting therapy: obtain a fasting lipid panel, hepatic transaminases (ALT, AST), and a baseline CK level. Record height, weight, BMI percentile, and Tanner stage. The AAP recommends confirming the lipid abnormality on at least two fasting samples drawn 2 weeks apart before initiating pharmacotherapy [3].

At 4 weeks and after each dose change: repeat the fasting lipid panel and ALT/AST. The FDA label states that liver enzyme monitoring should occur at 12 weeks after initiation or dose escalation and periodically thereafter [1].

Every 6 to 12 months on stable therapy: fasting lipids, ALT/AST, height, weight, and Tanner staging. CK measurement is not required routinely but should be obtained if the child reports new muscle pain, tenderness, or weakness [1].

Growth velocity deserves particular attention. The 20-year follow-up study by Braamskamp et al. (2019) followed 214 children with FH who started statins in childhood (mean age at initiation: 13.0 years). Adult height, weight, BMI, and reproductive outcomes did not differ significantly between statin-treated patients and their unaffected siblings [7]. While this study used primarily pravastatin and not rosuvastatin, it provides the longest available reassurance that pediatric statin exposure does not impair growth or reproductive health.

A child whose height velocity drops below the 5th percentile for age during statin therapy warrants a pause in treatment and endocrinology referral.

Drug Interactions and Contraindications Specific to Pediatric Patients

Several interactions carry heightened relevance in children.

Cyclosporine is contraindicated with rosuvastatin at any dose. Some children under 12 take cyclosporine after solid-organ transplantation. If these patients require a statin, rosuvastatin is not an option [1].

Gemfibrozil combined with rosuvastatin is also contraindicated. Gemfibrozil raises rosuvastatin exposure approximately 2-fold by inhibiting its OATP1B1-mediated hepatic uptake, increasing myopathy risk [1].

Rosuvastatin is Pregnancy Category X. This is relevant even for children under 12 if a patient is approaching menarche. The prescribing information requires pregnancy counseling for any female patient of reproductive potential [1]. Practitioners should document this discussion in the chart.

Asian ancestry affects pharmacokinetics. Rosuvastatin systemic exposure is approximately 2-fold higher in patients of Asian descent compared with Caucasian patients, likely due to ABCG2 transporter polymorphisms. The FDA label recommends a starting dose of 5 mg in Asian adult patients [1]. While no pediatric-specific pharmacokinetic data exist for this population, the same caution applies. Consider conservative dosing and closer monitoring.

Antacids containing aluminum and magnesium hydroxide reduce rosuvastatin absorption by approximately 50% when taken simultaneously. Separate administration by at least 2 hours [1].

Why Not Other Statins for Children Under 12

Rosuvastatin is not the only pediatric-approved statin, but it is the most potent by milligram.

Pravastatin holds FDA approval for children as young as 8 with HeFH. Atorvastatin is approved for HeFH in patients 10 and older. Rosuvastatin's advantage is its LDL-C lowering potency per milligram: 5 mg of rosuvastatin produces roughly equivalent LDL reduction to 10 mg of atorvastatin or 40 mg of pravastatin [8]. This potency allows effective treatment at lower absolute doses, which some clinicians and families prefer.

The choice between statins in a child under 12 often comes down to the degree of LDL-C elevation. Dr. Sarah de Ferranti, a pediatric cardiologist at Boston Children's Hospital, has noted in published guidance: "For children with severe HeFH and LDL-C >250 mg/dL, we typically start with a more potent statin like rosuvastatin or atorvastatin because the LDL-C reduction needed to reach goal cannot be achieved with pravastatin at approved doses" [9].

Rosuvastatin also has minimal CYP3A4 metabolism, which reduces drug interaction risk compared with atorvastatin and simvastatin. This can be relevant in children taking medications metabolized through the same pathway (certain antifungals, macrolide antibiotics commonly prescribed in pediatric infections) [1].

When to Refer to a Pediatric Lipid Specialist

Not every pediatrician manages pediatric statin therapy independently. Certain scenarios warrant subspecialty input.

A child under 12 with suspected or confirmed HoFH should be referred to a lipid specialist or pediatric cardiologist with FH expertise before starting any therapy. HoFH often requires combination treatment and possibly LDL apheresis, neither of which falls within general pediatric practice. The European Atherosclerosis Society (EAS) consensus panel recommends that all HoFH patients, regardless of age, be managed at or in consultation with a specialized lipid center [10].

Additional referral triggers include: LDL-C persistently above 190 mg/dL despite maximally tolerated rosuvastatin plus ezetimibe, unexplained CK elevations exceeding 5 times the upper limit of normal, suspected statin intolerance with myalgia on two or more statins, and any child under age 8 with severe dyslipidemia who may need off-label statin therapy.

Children with FH and additional risk factors (type 1 diabetes, Kawasaki disease with coronary aneurysms, chronic kidney disease, or post-transplant status) also benefit from specialist co-management [3].

Long-Term Safety Considerations and Parental Concerns

Parents frequently ask whether statins are safe for growing children. The evidence is reassuring, though not unlimited in duration.

The Braamskamp et al. 20-year follow-up is the longest prospective study of statin therapy initiated in childhood. Among 214 patients with FH who began statins at a mean age of 13 years, adult height reached predicted values, and fertility outcomes (pregnancy rates, live birth rates) matched those of unaffected siblings [7]. Carotid intima-media thickness (cIMT), a surrogate for atherosclerosis progression, was significantly lower in statin-treated FH patients than in untreated FH patients, and it did not differ from unaffected siblings, suggesting that early statin therapy may normalize vascular aging [7].

Short-term adverse effects in children mirror those in adults. Headache, myalgia, abdominal pain, and nausea occur in 2% to 5% of pediatric patients [5]. Rhabdomyolysis has not been reported in pediatric rosuvastatin trials but remains a theoretical risk, as with all statins.

Neurocognitive effects have been studied specifically in pediatric statin users. A 2016 analysis published in the Journal of Pediatrics found no measurable differences in cognitive function, school performance, or behavior between children on statin therapy and matched controls [11].

One gap in the literature: no randomized trial has followed children who started rosuvastatin before age 10 for longer than 2 years. The reassurance from Braamskamp and similar studies comes largely from pravastatin data, and the population studied was predominantly adolescent at initiation. For children starting rosuvastatin at age 7 or 8, clinicians are extrapolating from a relatively thin evidence base.

Practical Administration Tips

Giving a pill to a 7-year-old is not always straightforward.

Rosuvastatin tablets (5 mg, 10 mg, 20 mg, 40 mg) can be crushed and suspended in water for immediate administration. No commercial liquid formulation exists, but compounding pharmacies can prepare suspensions with a beyond-use date of 14 days at room temperature or 28 days refrigerated, using a vehicle such as Ora-Sweet [1]. Sprinkle the crushed tablet on a spoonful of applesauce if the child resists water suspension.

Timing is flexible. Rosuvastatin can be taken morning or evening, with or without food. Unlike some statins (simvastatin, lovastatin), it does not require evening dosing because its half-life is approximately 19 hours [1].

Adherence drops when children feel no symptoms and take a daily medication for a problem they cannot perceive. Consider using a visual chart or app-based reminder. Involve the child in understanding their condition at an age-appropriate level. A 10-year-old can comprehend "your body makes too much cholesterol because of a gene you inherited, and this medicine helps keep your blood vessels healthy."